Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -551K | -571K | -2M | -685K |
| Operating Income | -22M | -32M | -37M | -49M | -37M |
| EBITDA | -21M | -30M | -33M | -47M | -35M |
| Net Income | -21M | -30M | -34M | -49M | -37M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$17.82
+7.03% today
1Y Change
+61.29%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sensei Biotherapeutics, Inc. (SNSE) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $17.82 and up 61.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -1293.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -1293.3%, free cash flow +17.5% with operating margin 459.5% and ROIC -110.9%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNSE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNSE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNSE Max Drawdown
-69.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNSE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$36.8M
+24.3% YoY
Free Cash Flow
-$32.3M
+17.9% YoY
Revenue Growth
+0.0%
EPS Growth
-1293.3%
Gross Margin
0.0%
Net Margin
434.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -551K | -571K | -2M | -685K |
| Operating Income | -22M | -32M | -37M | -49M | -37M |
| EBITDA | -21M | -30M | -33M | -47M | -35M |
| Net Income | -21M | -30M | -34M | -49M | -37M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9M | 10M | 13M | 18M | 7M |
| Total Assets | 23M | 45M | 74M | 118M | 153M |
| Total Liabilities | 4M | 7M | 9M | 15M | 7M |
| Shareholder Equity | 19M | 38M | 65M | 103M | 147M |
| Total Debt | 2M | 4M | 6M | 8M | 2M |
| Net Debt | -7M | -6M | -7M | -10M | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
30M
+22.5% YoY
Capital Expenditures
2M
-531.2% YoY
Free Cash Flow
32M
+17.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
459.5%
Net Margin
434.7%
ROE
-83.6%
Debt / Equity
0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.